Testing a new tuberculosis vaccine for people with HIV
Evaluating the safety, immunogenicity and efficacy of a robust attenuated Mtb vaccine in the setting of HIV co-infection
This study is testing a new vaccine to help protect people with both tuberculosis and HIV, aiming to create a stronger and longer-lasting immune response than the current vaccine, and participants will receive the vaccine and be monitored for their health and immune reactions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Biomedical Research Institute NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11256995 on NIH RePORTER |
What this research studies
This research investigates a new vaccine designed to protect against tuberculosis (TB) in individuals co-infected with HIV. The vaccine uses an attenuated form of Mycobacterium tuberculosis, which is expected to generate a stronger and longer-lasting immune response compared to the currently used Bacille Calmette-Guerin (BCG) vaccine. The study will assess the safety, immunogenicity, and efficacy of this new vaccine in a controlled setting, aiming to provide better protection for vulnerable populations. Participants may receive the vaccine and be monitored for their immune responses and overall health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are co-infected with HIV and at risk of developing tuberculosis.
Not a fit: Patients who are not co-infected with HIV or those who have already received effective TB vaccinations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine against tuberculosis for individuals living with HIV, significantly improving their health outcomes.
How similar studies have performed: Previous research has shown promising results with similar approaches using attenuated vaccines, indicating potential for success in this novel application.
Where this research is happening
San Antonio, United States
- Texas Biomedical Research Institute — San Antonio, United States (Active)
Researchers
- Principal investigator: Kaushal, Deepak — Texas Biomedical Research Institute
- Study coordinator: Kaushal, Deepak
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.